# BenefReturn: __Private investors investing in this mitigation measure could benefit from improved asset value by supporting the development of targeted antimicrobial therapies and reducing the misuse of antimicrobials, leading to improved patient outcomes and decreased healthcare costs.__ (PBN__BenefReturn_224)

